Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6527
    +0.0027 (+0.41%)
     

  • OIL

    82.75
    -0.06 (-0.07%)
     

  • GOLD

    2,336.90
    -1.50 (-0.06%)
     

  • Bitcoin AUD

    97,681.54
    -3,995.80 (-3.93%)
     

  • CMC Crypto 200

    1,361.09
    -21.49 (-1.55%)
     

  • AUD/EUR

    0.6083
    +0.0012 (+0.20%)
     

  • AUD/NZD

    1.0953
    +0.0011 (+0.10%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,094.58
    +54.20 (+0.67%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    17,986.99
    -101.71 (-0.56%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ

Opthea Limited
·2-min read
Opthea Limited
Opthea Limited

MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that management will participate in the one-on-one meeting portion of the H.C. Wainwright BioConnect Conference being held on May 2, 2023. The Conference is produced in partnership with NASDAQ and will take place at the exchange’s world headquarters in New York City (151 West 42nd Street).

About Opthea Limited

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

ADVERTISEMENT

Inherent risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.

Authorized for release to ASX by Megan Baldwin, CEO & Managing Director

Company & Media Enquiries:

 

 

 

U.S.A. & International:

 

Australia:

Timothy E. Morris, CFO

 

Rudi Michelson

Opthea Limited

 

Monsoon Communications

Tel: +1 650-400-6874

 

Tel: +61 (0) 3 9620 3333

 

 

 

Media:

 

Join our email database for updates:

Hershel Berry

 

Tel: +61 (0) 3 9826 0399

Blueprint Life Science Group

 

Email: info@opthea.com

Tel: +1 415 505 3749

 

Web: www.opthea.com

hberry@bplifescience.com